Personalized T-Cell therapy takes on advanced lung cancer

NCT ID NCT07673419

Not yet recruiting Disease control Sponsor: Beijing Geekgene Technology Co., LTD Source: ClinicalTrials.gov ↗

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This early-stage trial tests a new cell therapy called GK01 for people with advanced lung cancer who have not responded to standard treatments. The therapy uses a patient's own immune cells (T cells) that are specially prepared to attack the cancer. The main goal is to check safety, but researchers will also look for signs that the treatment shrinks tumors or controls the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: GK01 cell injection (autologous tumor-reactive T cells)
What this could lead to: If successful, this could offer a new treatment option for people with advanced lung cancer who have run out of standard therapies.
What could go wrong: This is a very early, small trial (10 people) focused on safety. The treatment may not shrink tumors or may cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED LUNG CANCER

Contacts and locations

Locations

Peking University Cancer Hospital

Beijing, China
Peking University Cancer Hospital

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.